Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biomerica (BMRA) EBITDA (2016 - 2026)

Biomerica's EBITDA history spans 17 years, with the latest figure at -$1.3 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 12.71% to -$1.3 million in Q1 2026 year-over-year; TTM through Feb 2026 was -$4.2 million, a 14.32% increase, with the full-year FY2025 number at -$5.0 million, up 16.65% from a year prior.
  • EBITDA hit -$1.3 million in Q1 2026 for Biomerica, up from -$1.3 million in the prior quarter.
  • Over the last five years, EBITDA for BMRA hit a ceiling of $4000.0 in Q3 2025 and a floor of -$2.1 million in Q3 2022.
  • Historically, EBITDA has averaged -$1.3 million across 5 years, with a median of -$1.4 million in 2024.
  • Biggest five-year swings in EBITDA: plummeted 1460.36% in 2023 and later soared 100.3% in 2025.
  • Tracing BMRA's EBITDA over 5 years: stood at -$1.6 million in 2022, then grew by 7.83% to -$1.5 million in 2023, then soared by 36.7% to -$954000.0 in 2024, then tumbled by 38.47% to -$1.3 million in 2025, then rose by 0.68% to -$1.3 million in 2026.
  • Business Quant data shows EBITDA for BMRA at -$1.3 million in Q1 2026, -$1.3 million in Q4 2025, and $4000.0 in Q3 2025.